1 Notable transmitted HIV drug resistance among people who

2 inject drugs in Pakistan

3	
4	Stephanie Melnychuk ^{1,2} , Laura H. Thompson ³ , Chris Archibald ³ , James F. Blanchard ¹ , Faran
5	Emmanuel ¹ , Tahira Reza ⁴ , Nosheen Dar ⁵ , Paul Sandstrom ² , Souradet Y. Shaw ¹ , Marissa L.
6	Becker ¹ , François Cholette ^{2,6} *
7	
8	¹ Institute for Global Public Health, Department of Community Health Sciences, University of
9	Manitoba, Winnipeg, Canada
10	² National Sexually Transmitted and Blood Borne Infection Laboratory, National Microbiology
11	Laboratory at the J.C. Wilt Infectious Diseases Research Centre, Public Health Agency of
12	Canada, Winnipeg, Canada
13	³ Sexually Transmitted and Bloodborne Infections Surveillance Division, Centre for
14	Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa,
15	Ontario, Canada
16	⁴ Centre for Global Public Health, Pakistan, Chak Shahzad, Islamabad, Pakistan
17	⁵ Canada-Pakistan HIV/AIDS Surveillance Project, Islamabad, Pakistan
18	⁶ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine,
19	University of Manitoba, Winnipeg, Canada.
20	
21	*Corresponding author:

22 Email: <u>francois.cholette@phac-aspc.gc.ca</u> (FC)

23 Abstract

24	Transmission of drug-resistant HIV strains to treatment-naïve patients can compromise
25	antiretroviral therapy (ART) effectiveness and lead to treatment failure. In Pakistan, transmitted
26	HIV drug resistance among people who inject drugs (PWID) is fuelled by a lack of ART, poor
27	drug adherence, and unsafe injection practices, resulting in efficient transmission in large
28	injecting networks. A cross-sectional study was conducted among PWID recruited in the
29	Pakistani cities of Karachi, Larkana, Peshawar, Quetta and Hyderabad (August 2014 to January
30	2015). A portion of the HIV pol gene was amplified from HIV-reactive dried blood spot
31	specimens ($n=282/367$) and sequenced using an in-house Sanger sequencing assay for HIV drug
32	resistance mutation genotyping. Drug resistance mutations (DRMs) were identified using the
33	Stanford University HIV Drug Resistance Database HIVdb algorithm
34	(<u>https://hivdb.stanford.edu/hivdb</u>). Overall, HIV subtype A1 was dominant (78.0%; <i>n</i> =220),
35	followed by CRF02_AG (15.6%; <i>n</i> =44), CRF35_AD (2.5% <i>n</i> =7), recombinants (3.5%; <i>n</i> =10),
36	and subtype C (0.4% $n=1$). DRM analysis identified over half (63.8%) of participants harbored at
37	least one DRM, of which 28.9% reported using help from a professional injector. Nearly all
38	(99.4%) participants were not actively receiving ART because most (88.7%) had never
39	undergone HIV testing and were unaware of their status. Findings suggest significant transmitted
40	HIV drug resistance present among PWID, exacerbated by unsafe injection practices,
41	particularly professional injection. Low testing rates signal a need for more comprehensive
42	testing programs to improve HIV status awareness and ART coverage in Pakistan. Given most
43	treatment-naïve participants had evidence of drug resistance, drug resistance genotyping prior to
44	ART initiation might aid in ensuring effective treatment to prevent transmission of resistant HIV
45	strains.

47 Introduction

48	In Pakistan, HIV prevalence is estimated to be 0.1% in the general population, but is
49	known to be much higher among people who inject drugs (PWID), with estimates as high as
50	40% of PWID in the country living with HIV (1,2). This considerable burden is attributable to
51	the marginalization of PWID due to contextual factors, including illiteracy, poverty,
52	homelessness, and criminalization (3-5), which constrain access to both harm reduction
53	programs and antiretroviral therapy (ART) (6). Further, the requirement of individuals actively
54	injecting drugs to undergo a two-week drug detoxification prior to ART initiation (7) and lack of
55	a national opioid substitution therapy program in Pakistan presents structural barriers which
56	might contribute to higher rates of HIV transmission among PWID overall, hindering effective
57	HIV management and posing challenges to overall HIV epidemic control efforts in the country
58	(8–10).
59	PWID undergoing ART have increased vulnerability to treatment interruptions due to a
60	lack of social support and stable housing, mental health comorbidities, and effects of stigma and
61	discrimination (9,11,12). Suboptimal therapy and non-adherence to ART facilitates the selection
62	of viral strains harboring drug resistance mutations (DRMs) (13) which can be transmitted to
63	ART-naïve individuals, constituting what is defined as transmitted drug resistance (14).
64	Transmitted drug resistance poses challenges to virological suppression and achieving
65	undetectable viral loads in ART-naïve patients harboring DRMS (15,16), with studies
66	documenting high risk of failing first-line therapy in ART-naïve patients harboring DRMs (17-
67	19).
60	The discusses of boundary of the new itted data and istance for in a DWID many he facilled

68 The disproportionate burden of transmitted drug resistance facing PWID may be fuelled
69 by the rapid and efficient transmission of drug-resistant HIV strains in large, interconnected

70	injecting networks with high frequency of sharing injecting equipment (20,21) in certain
71	contexts, including Pakistan (22). High daily injection frequency (23), sharing syringes and other
72	drug use paraphernalia (22), injection of shared blood-drug mixtures (24), and help from
73	professional injectors (3), have been previously identified as risk factors among PWID in
74	Pakistan.
75	Few studies have looked at baseline HIV DRMs among people living with HIV in
76	Pakistan (5,25–27), with even fewer looking specifically at PWID. Knowledge of DRMs is
77	essential for guiding ART selection, as ARTs are currently prescribed in Pakistan without
78	baseline drug resistance genotyping (26). This increases the risk of ineffective treatment. Using
79	data from a cross-sectional survey conducted in 2014 (28), we sought to assess HIV drug
80	resistance in PWID across five major cities in Pakistan.
01	

81

82 Material and Methods

83 Study setting

For this cross-sectional study, PWID were recruited from August 2014 to January 2015
across five major cities in Pakistan. To ensure accurate reflection the study population, a detailed
mapping of size, geography, and operation typology of the PWID population was conducted
prior to the survey as described previously elsewhere (29).
Following informed consent, participants were interviewed to collect information

89 pertaining to sociodemographics, drug use practices, and utilization of HIV prevention and care

90 services, as well as a dried blood spot (DBS) specimen.

91 HIV serology and *pol* sequencing

DBS were shipped to the National Sexually Transmitted and Blood Borne Infection
Laboratory (Public Health Agency of Canada, Winnipeg, Canada). Serological testing using the
AVIOQ HIV Microelisa System (Avioq Inc., Durham, NC) was performed according to the
manufacturer's instructions. HIV drug resistance mutation genotyping was attempted on all HIVreactive DBS.

A routine, in-house HIV drug resistance mutation genotyping assay was used to amplify
and sequence a portion of the *pol* open reading frame (nt 2,074–3,334 on HXB2, <u>K03455</u>) from
DBS as previously described (28). Sequence analysis and contig assembly was performed using
RECall (30). HIV *pol* sequences are available via a public repository (i.e. NCBI) under accession
numbers MN887780-MN888069.

102 HIV subtyping and drug resistance mutation analysis

103 PWID HIV pol sequences were aligned, visually inspected, and manually edited in 104 MEGA v7 (31) as required. Subtyping was carried out using REGA HIV automated subtyping 105 tool v3 (32) and COMET (33), with SCUEAL (34) used as a tiebreaker for discordant results. 106 The Stanford HIV Drug Resistance Database program v9.4.1 (https://hivdb.stanford.edu) 107 (35) was used to assess for mutations in the HIV *pol* gene associated with resistance to protease 108 and reverse transcriptase inhibitors. Sequences containing one or more DRMs were considered 109 drug-resistant (DR). Any DRMs identified for which no clinical implications were found in the 110 literature were discarded.

111 Statistical analyses

112 Descriptive statistics were calculated for sociodemographic and behavioral information. 113 Pearson's chi-square test was applied between DR classification and predictor variables using 114 SciPy (36), where P<0.050 was used to define statistically significant associations.

115 Ethics

123	Results
122	
121	as an additional measure of protecting their identities.
120	study. Verbal consent was chosen due to varying levels of literacy among study participants and
119	the data collection team for the behavioural survey and biological sampling components of this
118	Informed consent was obtained verbally from study participants and documented by a member of
117	University of Manitoba [HS15691(H2012:294)] and BRIDGE Consultants Foundation, Pakistan.
116	Ethics board approval was obtained from the Health Research Ethics Board at the

124 Study population and sequence dataset

A total of 1,453 PWID consented to participate in the study from Karachi (n = 300),
Larkana (n = 300), Peshawar (n = 253), Quetta (n = 300) and Hyderabad (n = 300). All
participants consented to providing a DBS sample. Serological testing identified 367 (25.5%)
PWID living with HIV.

129 Of the HIV-reactive DBS specimens, 287 pol sequences (79.0%) were amplified – 130 corresponding to 80% of HIV-reactive DBS from each city except Hyderabad, where 131 amplification success was closer to 70%. In accordance with WHO HIV drug resistance criteria 132 (37), five sequences containing premature stop codons were removed from subsequent analysis. 133 Of 282 *pol* sequences, 109 (38.7%) were from Karachi, 90 (31.9%) from Peshawar, 39 (13.8%) 134 from Hyderabad, 25 (8.9%) from Larkana, and 19 (6.7%) from Quetta. Most sequences were 135 classified as subtype A1 (n=220, 78.0%), followed by CRF02 AG (n=44, 15.6%), CRF35 AD 136 (n=7, 2.5%), recombinants (n=10, 3.5%), and subtype C (n=1, 0.4%).

137 Sociodemographic characteristics

138 Sociodemographic and behavioral information of PWID for whom HIV sequences were 139 obtained is presented in Table 1. All participants were male. Of 282 sequences analyzed, 180 140 (63.8%) were considered DR. 141 Statistically significant predictors of DR classification were city of residence and age 142 (P<0.05) (Table 1). Years injecting, daily injection frequency, injection method, and ART status 143 were not significantly associated with DR. Prevalence of DR ranged from 33.3% to 94.7% 144 among participants when stratified by city. Of those with DR sequences, the highest proportion 145 (39.4%) were between 25-29 years of age. Using help from a professional injector was slightly 146 higher in DR participants (28.9%). Of participants who had undergone HIV testing and were 147 aware of their positive status (n=32, 11.3%), one (3.1%) was actively receiving ART.

148

149 Table 1. Sociodemographic and behavioral characteristics of people who inject drugs in

150 Pakistan stratified according to presence of drug resistance mutations in HIV sequences.

Variable	DR (≥1 DRM) (<i>N</i> =180)	Non-DR (<i>N</i> =102)	<i>P</i> *
City, <i>n</i>			< 0.001
Hyderabad	35	4	
Karachi	75	34	
Larkana	22	3	
Peshawar	30	60	
Quetta	18	1	
Age, <i>n</i> (%)			0.010
<24	43 (23.9)	40 (39.2)	
25-29	71 (39.4)	26 (25.5)	
≧30	66 (36.7)	36 (35.3)	
Years injecting drugs, n (%) ^a			0.200
<2	32 (17.8)	21 (20.6)	

2-4	64 (35.6)	44 (43.1)	
≧5	84 (46.7)	36 (35.3)	
Times injecting the previous day, n (%)			0.130
0	45 (25.0)	15 (14.7)	
1	74 (41.1)	48 (47.1)	
≧2	61 (31.7)	39 (37.3)	
Injection method at last injection, n (%)			0.200
Without help	104 (57.8)	70 (68.6)	
Uses help, but not from a professional injector	24 (13.3)	10 (9.8)	
Uses help from a professional injector	52 (28.9)	22 (21.6)	
Current ART treatment status, <i>n</i> (%)			0.720
No	19 (10.6)	12 (11.8)	
Yes	1 (0.6)	0 (0.0)	
Not specified ^b	160 (88.9)	90 (88.2)	

151 Table 1 legend:

152 **P*-value based on Pearson chi-square test.

^aAmong respondents does not add to 100%.

¹⁵⁴ ^bLow response rate for HIV treatment is because most participants had never undergone HIV testing and

155 did not respond to questions regarding ART.

156

157 Analysis of HIV drug resistance analysis

158 HIV mutations associated with drug resistance are summarized in Table 2. Of 282

analysed HIV pol sequences, 13 DRMs were identified among the 180 DR participants: two

160 protease inhibitor (PI), two nucleoside RT inhibitor (NRTI), and nine non-nucleoside RT

161 inhibitor (NNRTI) mutations (Table 2).

162

163 Table 2. Drug-resistance mutations in HIV sequences from people who inject drugs across

164 several Pakistani cities.

		All cities (<i>N</i> =282)	Hyderabad (<i>N</i> =39)	Karachi (N=109)	Larkana (<i>N</i> =25)	Peshawar (N=90)	Quetta (N=19)
DRM	As ^a , <i>n</i> (%)						
JIS	M46I*	1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
	L10F	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
TIS	K219R*	2 (0.7)	0 (0.0)	2 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
NR	S68G	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
	K101E*	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 2.2)	0 (0.0)
	K103N*	3 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.2)	1 (5.3)
	V106I	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
Is	E138A	164 (58.2)	34 (87.2)	70 (64.2)	22 (88.0)	21 (23.3)	17 (89.5)
NNRT	E138APQ	1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
	V179D	2 (0.7)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	1 (5.3)
	V179T	11 (3.9)	1 (2.6)	5 (4.6)	0 (0.0)	4 (4.4)	1 (5.3)
	V179IT	2 (0.7)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	1 (5.3)
	Y188H*	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
Genotype, <i>n</i> (%)							
A1		220 (78.0)	35 (89.7)	73 (67.0)	22 (88.0)	73 (81.1)	17 (89.5)
CRF 02_AG		44 (15.6)	1 (2.6)	29 (26.6)	3 (12.0)	10 (11.1)	1 (5.3)
R	EC ^b	10 (3.5)	2 (5.1)	1 (0.9)	0 (0.0)	7 (7.8)	0 (0.0)
C	CRF 35_AD	7 (2.5)	1 (2.6)	5 (4.6)	0 (0.0)	0 (0.0)	1 (5.3)
С		1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)

165 Table 2 legend:

166 *DRM belongs to WHO 2009 list of mutations for surveillance of HIV drug resistance (38).

- ¹⁶⁷ ^aPIs: M46I is associated with low- to intermediate-level resistance to indinavir, nelfinavir, fosamprenavir,
- 168 lopinavir, saquinavir, and atazanavir (39); and L10F is an accessory DRM associated with reduced
- 169 lopinavir and darunavir susceptibility (40). NRTIs: K219R confers resistance to azidothymidine (41,42);
- 170 and S68G is associated with K65R mutants to improve viral replication (43). NNRTIS: K101E confers
- 171 highly-reduced susceptibility to nevirapine and decreases efavirenz, etravirine, and rilpivirine
- susceptibility (44); K103N is associated with resistance to nevirapine and efavirenz (45,46); V106I
- 173 confers potential low-level resistance to doravirine, etravirine, nevirapine, and rilpivirine (47); E138A and
- 174 E138Q confer reduced susceptibility to etravirine and reduced, potentially full, susceptibility to rilpivirine
- 175 (48,49); V179D is associated with low-level resistance to efavirenz, nevirapine, etravirine, and rilpivirine
- 176 (50); V179T has been reported with reduced susceptibility to etravirine in the presence of other DRMs
- 177 (51); V179I is associated with resistance to etravirine and rilpivirine (52); and Y188H has been reported
- 178 to confer resistance to nevirapine and efavirenz (53).
- 179 ^b"REC" indicates sequences classified as recombinants.
- 180

DRM E138A was the most common mutation across all cities (58.2%), with almost all sequences from Hyderabad, Larkana, and Quetta containing this mutation (87.2%, 88.0%, and 89.5%, respectively). Karachi sequences had the only reports of DRMs M46I, K219R, and V179T. Despite Peshawar having the smallest percentage (33.3%) of sequences containing any DRMs, these sequences had the most diversity, containing 7 of the 13 DRMs in our analysis, including the only observances of L10F, S68G, K101E, and V106I. The mutation K103N was only reported in two sequences from Peshawar and one sequence from Quetta.

189 **Discussion**

190 Here, we present HIV drug resistance mutations from a cross-sectional survey conducted 191 in 2014 among PWID from five cities in Pakistan. Our analysis demonstrated a high prevalence 192 of DRMs associated with NNRTI resistance. The vast majority of participant sequences from 193 Hyderabad (89.7%), Karachi (68.8%), Larkana (88.0%), and Quetta (94.7%) contained at least 194 one DRM. Given that only one (0.6%) study participant reported actively receiving ART, 195 observing DRMs in high frequency among participants suggests significant HIV transmitted 196 drug resistance present among PWID in Pakistan. 197 Over half (58.2%) of PWID in our study harbored E138A, conferring low-level resistance 198 to the NNRTIs etravirine and rilpivirine (48,49). Other studies have observed E138A among 199 people living with HIV in Pakistan, reporting varying prevalence in ART-experienced (13-78%) 200 and ART-naïve (8-39%) cohorts (5.27). Perhaps more concerning are the DRMs observed in low 201 prevalence conferring resistance to efavirenz– namely K101E (44), K103N (45,46), V179D (50), 202 and V188H (53). Pakistan's first-line ART regimen for adults is currently tenofovir and 203 lamivudine with dolutegravir (54), although efavirenz was formerly used in first-line regimes at 204 the time of our study (55) and is currently suggested for use in alternate regimes. Our results 205 suggest first-line regimes would be effective treatment for most PWID living with HIV who 206 participated in our study, although this might not be true for previous regimes. While Pakistan 207 has second-line regimens, these drugs are more prone to shortages compared with first-line 208 regimes (56), posing challenges to HIV treatment in individuals harboring resistance to efavirenz 209 prior to the change to dolutegravir in 2019 (57) and enabling transmission of drug-resistant 210 strains. 211 We observed city of residence and age to be significantly associated with DR

212 classification. Participants with DR sequences reported slightly higher prevalence of help from a

12

213 professional injector compared to non-DR sequences (28.9% versus 21.6% respectively), and 214 while method at last injection was not significantly associated to DR, we did not stratify the 215 analysis by city and injection method to determine its significance for each study city. 216 Professional injectors (or street doctor) are PWID themselves who reuse the same injecting 217 equipment to inject several clients – often younger and inexperienced PWID – daily, for a fee 218 (58-60). This fee can be something known as "scale", a blood-drug mixture collected by the 219 professional injector by double-pumping the syringe, which is then sold to other PWID for less 220 than the regular drug (22,28,61), allowing for efficient transmission of drug-resistant HIV. Using 221 help from professional injectors has previously been reported to be more prevalent in Karachi 222 (53.7%) compared to Peshawar (25.2%) and Quetta (19.6%) (59). Differences in DRM 223 prevalence among cities might also be partially explained by varying rates of heroin injection, 224 observed to be high in Karachi and Quetta (96.9% and 81.1% respectively) (59). Heroin has been 225 associated with high-risk injection practices, such as needle sharing and "jerking", where heroin 226 is mixed with blood and shared amongst injectors (6), facilitating transmission of resistant strains 227 among PWID.

228 In this study, we report the spread of drug-resistant HIV is likely being fuelled by the 229 lack of ART coverage among PWID participants, permitting high viral loads which enable 230 efficient HIV transmission. Our findings stress the lack of ART coverage among PWID in 231 Pakistan, known to still be an ongoing issue and major obstacle to HIV treatment in the country. 232 The low ART coverage observed in our study is likely due in part to the lack of participants' 233 awareness that they are living with HIV overall, as we observed nearly all (88.7%) PWID 234 participants to have never undergone HIV testing. Awareness of HIV status among people in 235 Pakistan is known to be low (21%), with people living with HIV actively receiving ART being

13

even lower (12%) (62). Moreover, it is well established that PWID face barriers to ART access,
specifically identifying Pakistan's lack of national opioid substitution therapy program as a key
intervention to HIV prevention that remains illegal (8,11).

239

240 Conclusions

241 By sequencing, genotyping, and assessing for HIV drug resistance, we have been able to 242 identify the circulating HIV strains and the level of drug resistance among PWID in Pakistan. 243 Overall, our study indicates that few DRMs are found amongst PWID in Pakistan conferring 244 low-level resistance to etravirine, rilpivirine, and efavirenz. While our results suggest the 245 majority of PWID in our study would be susceptible to current first-line ART regimes, perhaps 246 more concerning is their lack of awareness of HIV-positive status and extremely limited access 247 to treatment. These findings highlight a need for more comprehensive testing programs among 248 PWID to increase HIV status awareness and drug resistance genotyping prior to ART initiation 249 to ensure effective treatment of resistant HIV strains.

250

251 Acknowledgements

We thank the surveillance team for their efforts in mapping, data collection, specimen collection and data entry. We also thank the participants who took part in the surveys for their time and participation. We thank Kiana Kadivar (National Sexually Transmitted and Blood Borne Infection Laboratory) for her initial assistance with coordinating serological testing.

256 **References**

- 1. UNAIDs. Country Progress Report Pakistan [Internet]. 2020 [cited 2023 Oct 29].
- 258 Available from:
- 259 <u>https://www.unaids.org/sites/default/files/country/documents/PAK_2020_countryreport.p</u>
- 260 <u>df</u>
- 261 2. UNAIDs. Country Factsheets: Pakistan [Internet]. 2022 [cited 2023 Aug 13]. Available
 262 from: https://www.unaids.org/en/regionscountries/countries/pakistan
- 263 3. Lim AG, Trickey A, Thompson LH, Emmanuel F, Reza TE, Reynolds R, et al.
- 264 Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus

265 Epidemic among People Who Inject Drugs in Pakistan. Open Forum Infect Dis.

- 266 2021;8(9).
- 267 4. Salman Y, Shaeen SK, Butt MS, Vohra LI, Hashmi T. HIV in Pakistan: Challenges,
 268 efforts and recommendations. Ann Med Surg. 2022;84.
- 269 5. Shah S, Xing H, Altaf A, Chen B, Liao L, Jia Y, et al. Antiretroviral drug resistance
- 270 mutations among treated and treatment-naive patients in Pakistan: Diversity of the HIV
- type 1 pol gene in Pakistan. AIDS Res Hum Retroviruses. 2011;27(12).
- 272 6. Capelastegui F, Trickey A, Thompson LH, Reza T, Emmanuel F, Cholette F, et al. Risk
- factors of HIV and variation in access to clean needles among people who inject drugs in
- 274 Pakistan. Pathog Glob Health. 2023;117(8).
- 275 7. Nai Zindagi Trust. ART adherence unit: A therapeutic community facility that aims to
- 276 improve HIV treatment outcomes for people who inject drugs in Pakistan [Internet]. 2016
- 277 [cited 2023 Nov 2]. Available from: <u>https://www.naizindagi.org/treatment-and-adherence/</u>

278	8.	Bergenstrom A, Achakzai B, Furqan S, ul Haq M, Khan R, Saba M. Drug-related HIV
279		epidemic in Pakistan: A review of current situation and response and the way forward
280		beyond 2015. Harm Reduct J. 2015;12(1).
281	9.	Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy
282		among HIV-infected drug users: A meta-analysis. AIDS Behav. 2010;14(4).
283	10.	Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJS, et al. The causal effect of
284		opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29(8).
285	11.	Iversen J, Qureshi S ul H, Zafar M, Busz M, Maher L. Adherence to antiretroviral therapy
286		among HIV positive men who inject drugs in Pakistan. Int J Drug Policy. 2021;96.
287	12.	Daud MY ousuf, Qazi RA ziz, Bashir N. Anti-retroviral drugs compliance in intravenous
288		and non intravenous drug abusers. J Ayub Med Coll Abbottabad. 2014;26(4).
289	13.	Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between
290		Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug
291		Resistance. Clin Infec Dis. 2003;37(8).
292	14.	WHO. HIV drug resistance report 2017 [Internet]. Geneva; 2017 [cited 2023 Dec 7].
293		Available from: https://iris.who.int/bitstream/handle/10665/255896/9789241512831-
294		<u>eng.pdf</u>
295	15.	McCluskey SM, Siedner MJ, Marconi VC. Management of Virologic Failure and HIV
296		Drug Resistance. Infect Dis Clin North Am. 2019;33(3).
297	16.	van Zyl G, Bale MJ, Kearney MF. HIV evolution and diversity in ART-treated patients.
298		Retrovirology. 2018;15(1).
299	17.	Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D,

300 Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on

- the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO
 survey. Lancet HIV. 2016;3(12).
- 303 18. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al.
- 304 HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in
- 305 low-income and middle-income countries: a systematic review and meta-regression
- analysis. Lancet Infect Dis. 2018;18(3).
- 307 19. Hamers RL, Schuurman R, Sigaloff KCE, Wallis CL, Kityo C, Siwale M, et al. Effect of
- 308 pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance
- 309 outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort
- 310 study. Lancet Infect Dis. 2012;12(4).
- 20. Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons
 who inject drugs: Ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6).
- 21. Pham QD, Wilson DP, Law MG, Kelleher AD, Zhang L. Global burden of transmitted
- 314 HIV drug resistance and HIV-exposure categories: A systematic review and meta-
- 315 analysis. AIDS. 2014;28(18).
- 316 22. Emmanuel F, Archibald C, Razaque A, Sandstrom P. Factors Associated With an
- 317 Explosive HIV Epidemic Among Injecting Drug Users in Sargodha, Pakistan. JAIDS.
- 318 2009 May;51(1):85–90.
- 319 23. Samo RN, Altaf A, Agha A, Pasha O, Rozi S, Memon A, et al. High HIV incidence
- 320 among persons who inject drugs in Pakistan: Greater risk with needle sharing and
- 321 injecting frequently among the homeless. PLoS One. 2013;8(12).

322	24.	Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk
323		environment for injecting drug users: The past, present, and future. Lancet.
324		2010;376(9737).
325	25.	Khan S, Zahid M, Qureshi MA, Mughal MN, Ujjan ID. HIV-1 genetic diversity,
326		geographical linkages and antiretroviral drug resistance among individuals from Pakistan.
327		Arch Virol. 2018;163(1).
328	26.	Siddiqui D, Badar U, Javaid M, Farooqui N, Shah SA, Iftikhar A, et al. Genetic and
329		antiretroviral drug resistance mutations analysis of reverse transcriptase and protease gene
330		from Pakistani people living with HIV-1. PLoS One. 2023;18(8 August).
331	27.	Abidi SH, Nduva GM, Siddiqui D, Rafaqat W, Mahmood SF, Siddiqui AR, et al.
332		Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive
333		Paediatric HIV-1 Outbreak in Larkana, Pakistan. Front Microbiol. 2021;12.
334	28.	Cholette F, Joy J, Pelcat Y, Thompson LH, Pilon R, Ho J, et al. HIV-1 phylodynamic
335		analysis among people who inject drugs in Pakistan correlates with trends in illicit opioid
336		trade. PLoS One. 2020 Aug 28;15(8):e0237560.
337	29.	Emmanuel F, Blanchard J, Zaheer HA, Reza T, Holte-Mckenzie M. The HIV/AIDS
338		Surveillance Project mapping approach: An innovative approach for mapping and size
339		estimation for groups at a higher risk of HIV in Pakistan. AIDS. 2010;24(SUPPL. 2).
340	30.	Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al. Automating
341		HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J
342		Clin Microbiol. 2012;50(6).
343	31.	Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular evolutionary
344		genetics analysis across computing platforms. Mol Biol Evol. 2018;35(6).

J = J = J = J = J	345	32.	Pineda-Peña AC	, Faria NR.	Imbrechts S.	Libin P.	Abecasis AB	Deforche K.	et al
-------------------	-----	-----	----------------	-------------	--------------	----------	-------------	-------------	-------

- 346 Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes:
- 347 Performance evaluation of the new REGA version 3 and seven other tools. Infect Genet
- 348 Evol. 2013;19.
- 349 33. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: Adaptive context-
- based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res.
- 351 2014;42(18).
- 352 34. Pond SLK, Posada D, Stawiski E, Chappey C, Poon AFY, Hughes G, et al. An
- 353 evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and
- 354 subtype prediction in HIV-1. PLoS Comput Biol. 2009;5(11).
- 355 35. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human
- immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic
 Acids Res. 2003;31(1).
- 358 36. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy
- 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3).
- 360 37. WHO. WHO HIVResNet HIV drug resistance laboratory operational framework, second
- 361 edition. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO; 2020.
- 362 38. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug
- resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
 PLoS One. 2009;4(3).
- 365 39. Bansode V, Drebert ZJ, Travers SAA, Banda E, Molesworth A, Crampin A, et al. Drug
 366 resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural
 367 Malawi. AIDS Res Hum Retroviruses. 2011;27(4).

368	40.	Rhee SY, Tzou PL, Shafer RW. Temporal trends in hiv-1 mutations used for the
369		surveillance of transmitted drug resistance. Viruses. 2021;13(5).
370	41.	Rhee SY, Liu TF, Holmes SP, Shafer RW. HIV-1 subtype B protease and reverse
371		transcriptase amino acid covariation. PLoS Comput Biol. 2007;3(5).
372	42.	Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, et al. Standardized
373		comparison of the relative impacts of HIV-1 Reverse Transcriptase (RT) mutations on
374		nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012;56(5).
375	43.	Li S, Ouyang J, Zhao B, An M, Wang L, Ding H, et al. The S68G polymorphism is a
376		compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE
377		strains. BMC Infect Dis. 2020;20(1).
378	44.	Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, et al. Role of the
379		K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other
380		nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother.
381		2013;57(11).
382	45.	Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q, et al. The development of drug
383		resistance mutations K103N Y181C and G190A in long term Nevirapine-containing
384		antiviral therapy. AIDS Res Ther. 2014;11(1).
385	46.	Chin BS, Shin HS, Kim G, Wagner GA, Gianella S, Smith DM. Short communication:
386		Increase of HIV-1 K103N transmitted drug resistance and its association with Efavirenz
387		use in South Korea. AIDS Res Hum Retroviruses. 2015;31(6).
388	47.	Yan L, Yu F, Zhang H, Zhao H, Wang L, Liang Z, et al. Transmitted and acquired hiv-1
389		drug resistance from a family: A case study. Infect Drug Resist. 2020;13.

390	48.	Kuznetsova A, Lebedev A, Gromov K, Kazennova E, Zazzi M, Incardona F, et al.
391		Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the
392		efficacy of first-line antiretroviral therapy regimens using rilpivirine in human
393		immunodeficiency virus-infected patients. Clin Case Rep. 2022;10(2).
394	49.	Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, et
395		al. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their
396		interactions with the M184I mutation on defining patterns of resistance to nonnucleoside
397		reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrob Agents Chemother.
398		2013;57(7).
399	50.	Liu Y, Zhang Y, Li H, Wang X, Jia L, Han J, et al. Natural presence of the V179D and
400		K103R/V179D mutations associated with resistance to nonnucleoside reverse
401		transcriptase inhibitors in HIV-1 CRF65_cpx strains. BMC Infect Dis. 2020;20(1).
402	51.	Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance
403		profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from
404		the randomized, controlled Phase III clinical studies. AIDS. 2010;24(4).
405	52.	Stanford University HIV Drug Resistance Database. NNRTI Resistance Notes [Internet].
406		2022 [cited 2023 Sep 4]. Available from: https://hivdb.stanford.edu/dr-
407		summary/resistance-notes/NNRTI/
408	53.	Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, et al.
409		Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on
410		susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents

411 Chemother. 2015;59(2).

- 412 54. NACP. Consolidation Guidelines for the Prevention and Treatment of HIV and AIDS in
- 413 Pakistan [Internet]. 2020 [cited 2024 Jan 9]. Available from:
- 414 https://nacp.gov.pk/howwework/technicalguidelinestac.html
- 415 55. NACP. Consolidated Guidelines for the Treatment of HIV and AIDS in Pakistan
- 416 [Internet]. 2015 [cited 2024 Jan 9]. Available from:
- 417 <u>https://nacp.gov.pk/howwework/technicalguidelinestac.html</u>
- 418 56. Mohan A, Shaikh MTA, Wara UU, Rackimuthu S, Costa AC dos S, Lal PM, et al.
- 419 HIV/AIDS among children in Ratodero, Pakistan amidst the COVID-19 pandemic:
- 420 Challenges, efforts, and recommendations. Clin Epidemiol Glob Health. 2021;12.
- 421 57. WHO. Who. 2019 [cited 2024 Jan 10]. Update of recommendations on first- and second422 line antiretroviral regimens. Available from:
- 423 https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15
- 424 58. Emmanuel F, Fatima M. Coverage to curb the emerging HIV epidemic among injecting
- 425 drug users in Pakistan: Delivering prevention services where most needed. Int J Drug
- 426 Policy. 2008;19(SUPPL. 1).
- 427 59. Archibald CP, Shaw SY, Emmanuel F, Otho S, Reza T, Altaf A, et al. Geographical and

428 temporal variation of injection drug users in Pakistan. Sex Transm Infect.

- 429 2013;89(SUPPL. 2).
- 430 60. Emmanuel F, Salim M, Akhtar N, Arshad S, Reza TE. Second-generation surveillance for
- 431 HIV/AIDS in Pakistan: results from the 4th round of Integrated Behavior and Biological
- 432 Survey 2011–2012. Sex Transm Infect. 2013 Nov;89(Suppl 3):iii23–8.

- 433 61. Khan AA, Awan AB, Qureshi SU, Razaque A, Zafar ST. Large sharing networks and
- 434 unusual injection practices explain the rapid rise in HIV among IDUs in Sargodha,
- 435 Pakistan. Harm Reduct J. 2009;6.
- 436 62. UNAIDS. UNAIDS DATA 2020 [Internet]. 2020 [cited 2023 Dec 11]. Available from:
- 437 https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf